Age, Biography and Wiki
Leonard Schleifer is an American doctor and businessman who is the founder, president, and CEO of Regeneron Pharmaceuticals, Inc. He was born in 1953 in Queens, New York, and graduated from the State University of New York at Stony Brook with a degree in biology. He then went on to earn his medical degree from the Albert Einstein College of Medicine in 1978.
Schleifer has been the CEO of Regeneron since 1988, and has been credited with leading the company to become one of the world’s leading biotechnology companies. He has also been a major contributor to the development of the company’s flagship product, Eylea, which is used to treat age-related macular degeneration.
Schleifer has been recognized for his work in the biotechnology industry, and has been awarded numerous awards, including the National Medal of Technology and Innovation in 2011. He has also been inducted into the National Academy of Sciences and the National Academy of Medicine.
As of 2021, Leonard Schleifer’s net worth is estimated to be roughly $1.5 billion.
| Popular As |
N/A |
| Occupation |
Doctor Businessman |
| Age |
70 years old |
| Zodiac Sign |
N/A |
| Born |
|
| Birthday |
|
| Birthplace |
Queens, New York, NY |
| Nationality |
United States |
We recommend you to check the complete list of Famous People born on .
He is a member of famous with the age 70 years old group. He one of the Richest who was born in United States.
Leonard Schleifer Height, Weight & Measurements
At 70 years old, Leonard Schleifer height not available right now. We will update Leonard Schleifer's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Who Is Leonard Schleifer's Wife?
His wife is Harriet Partel Schleifer
| Family |
| Parents |
Florence Schacht Schleifer Charles Baker Schleifer |
| Wife |
Harriet Partel Schleifer |
| Sibling |
Not Available |
| Children |
Adam Schleifer David Schleifer |
Leonard Schleifer Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is Leonard Schleifer worth at the age of 70 years old? Leonard Schleifer’s income source is mostly from being a successful . He is from United States. We have estimated
Leonard Schleifer's net worth
, money, salary, income, and assets.
| Net Worth in 2023 |
2.3 billion USD (2020) |
| Salary in 2023 |
Under Review |
| Net Worth in 2022 |
Pending |
| Salary in 2022 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
Leonard Schleifer Social Network
Timeline
The subject is currently working on a multi-center, double-blind, Phase 2/3 trial with the partnership Sanofi, to evaluate the antibody agent, Kevzara(TM) for hospitalized patients starting in March 2020, as well as, working on the development of a novel, multi-antibody cocktail to be used as both a prevention of SARS-CoV-2 and treatment for infected patients.
His son Adam is currently one of many candidates running for the nomination in the Democratic Primary for New York's 17th congressional district. The district comprises Central and Northern Westchester County and all of Rockland County. The current officeholder, Nita Lowey, is retiring from Congress.
As CEO Schleifer received a total compensation of $41,965,424 in 2014. According to the "annual collaborative report" from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of "200 highest-paid CEOs of large publicly traded companies." He ranked first in the list of biopharmaceutical executives with the highest total compensation.
As CEO of Regeneron, Schleifer oversaw the "approval and growth of high-priced drugs." In 2011, Regeneron's first successful drug was Eylea for age-related macular degeneration. Eylea prevented leaky blood vessels in the eye from causing blindness. He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a billionaire. In 2014 Eylea grossed $1.735 billion.
Noticing that the biotechnology company Genentech was conducting state-of-the-art research but not on diseases of the nervous system, he determined to get into the biotechnology business. After rebuking Gilman's efforts to recruit him as an academic, he found a sponsor in George Sing, a venture capitalist at Merrill Lynch, and obtained $1 million in seed capital. He also recruited George Yancopoulos, a 28-year-old scientist, to be his partner, and in 1988 they founded Regeneron Pharmaceuticals. After several years of trying to recruit research doctors many of whom preferred to work in academia or for large corporations, they developed their first drug to treat Lou Gehrig’s disease. It was a failure as was their second drug to treat obesity. Thereafter, they invited the former Merck & Co. CEO Roy Vagelos to be the chairman of their company and to help to turn the company around. He implemented two strategic changes; only invest in drugs in which the biology of the disorder is fully understood; and do not underestimate the importance of human testing to ensure that what works in the laboratory will also work in the real world.
Leonard S. Schleifer (born 1953) is the co-founder and chief executive of the biotechnology company Regeneron Pharmaceuticals.
